Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 106,020

Document Document Title
WO/2015/004163A1
The invention provides for tau antibodies, antibody-like scaffolds or antibody fragments with improved binding capacity for tau antigen. In particular, the invention provides for improved compositions, methods and kits comprising such an...  
WO/2015/004093A1
The present disclosure relates to the anticonvulsant activity of S. miltiorrhiza and tanshinones, and the use of compounds from S. miltiorrhiza as anticonvulsant agents for the treament of epilepsy and neurological disorders characterize...  
WO/2015/004485A1
The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown ...  
WO/2015/004240A1
The present invention relates to new nalmefene salts which salts fall within at least one of the two following categories: non-hydrate forming salts and non-solvate forming salts. In particular, the invention relates to the hydrogen adip...  
WO/2015/004371A1
The invention relates to a gaseous medication containing xenon, preferably in an amount of less than 75% by volume, for use by inhalation, in combination with at least one NMDA receptor antagonist in the form of a liquid or solid, in par...  
WO/2015/006280A9
The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods o...  
WO/2015/006569A2  
WO/2015/005459A1
 The present invention provides a pharmaceutical composition for respiratory administration containing a polysaccharide derivative having a group derived from a polysaccharide and a group derived from a biologically active substance co...  
WO/2015/005562A1
The present invention provides a composition including, as active ingredients, anthocyanin and a GABAB1R receptor agonist for providing effects for preventing and treating neurological disorders which are caused by nerve cell apoptosis, ...  
WO/2015/005491A1
Provided are a compound and a medicinal composition relating to a disease in which an abnormal splice variant participates, utilization of the same, and a method for searching for the same. In one or more embodiments, provided is a compo...  
WO/2015/004347A1
The invention relates to a gaseous medication containing xenon, to be used by inhalation for treating, slowing or preventing neurological deterioration resulting from Parkinson's disease in a human patient. The medication preferably cont...  
WO/2015/005443A1
 The purpose of the present invention is to provide an oral composition capable of actualizing a brain function-improving function and various other physiological functions. Specifically, the present invention provides an oral composit...  
WO/2015/004475A3
Compositions comprising an inhibitor of β-catenin for the treatment of spinal muscular atrophy (SMA) or a related neurological condition in a subject are presented, and methods of treating SMA using the same.  
WO/2015/005468A1
The present invention relates to a compound represented by general formula (II) having a P2X4 receptor antagonist action. (II) (In the formula, R1a to R6a are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, etc., Xa is C or N...  
WO/2015/005305A1
Provided is a compound which has an ALXR agonist activity. Specifically, the present invention provides a compound, represented by general formula (I) wherein all symbols have the same meanings as defined in the specification, a salt the...  
WO/2015/005467A1
The present invention relates to a compound represented by general formula (I) having a P2X4 receptor antagonist action. (I) (In the formula, R1, R2 and R3 are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group h...  
WO/2015/003723A1
The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are ...  
WO/2015/003793A1
The present invention relates to composition for use in inhibiting the reuptake of neurotransmitters and for inhibiting acetylcholinesterase comprising a concentrate or extract of at least one plant selected from the family of Cistaceae,...  
WO/2015/002119A1
Provided are: a compound indicated by a formula or a pharmaceutically acceptable salt thereof; and a pharmaceutical application therefor.  
WO/2015/000033A1
The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy by administering to a subject N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-(piperazin-1-y l)-4-o-tolyl nicotinamide or 4-alkyl-pipe...  
WO/2015/000921A1
The present invention relates to an activator of the PTGDS pathway for use in the treatment and/or prevention of a pathology characterized by an altered myelination in the nervous system.In particular the pathology is multiple sclerosis ...  
WO/2015/002118A1
Provided are: a compound indicated by a formula or a pharmaceutically acceptable salt thereof; and a pharmaceutical application therefor.  
WO/2015/002230A1
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)  
WO/2015/002537A1
The invention relates to the use of at least one amino acid, selected from the group of histidine, lysine, and threonine in the manufacture of a composition for use in the treatment of a pervasive development disorder, a neurogenetic syn...  
WO/2015/002450A1
The present invention provides a pharmaceutical composition or food composition comprising, as an active ingredient, Eclalbasaponin, a derivative thereof, or a herbal medicine extract containing Eclalbasaponin. The composition of the pre...  
WO/2015/001352A1
There are herein described new treatments for demyelinating diseases. More particularly,there is described here in the use of a novel regenerative therapy for the promotion of remyelination at a cellular level via remyelination of axons ...  
WO/2015/000800A1
The invention relates to the selective targeting of specific α2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In p...  
WO/2015/000833A1
The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions fo...  
WO/2015/002527A1
The invention relates to the use of at least one amino acid, selected from the group of histidine, lysine, and threonine in the manufacture of a composition for use in the treatment of a pervasive development disorder, a neurogenetic syn...  
WO/2015/001099A1
The invention relates to varenicline and/or topiramate for use in the treatment of impulse control disorders and/or the affective control of complex behavioral disorders of the nicotinergic and/or glutamatergic and/or dopaminergic neurot...  
WO/2015/000035A1
The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy by administering to a subject 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4 -yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.  
WO/2015/001379A1
It is disclosed a method for the treatment of neurodegenerative disorders, such as ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease and/or retinitis pigmentosa, which method comprises administering to a patient taurour...  
WO/2015/000034A1
The present invention relates to a method for the prevention and/or treatment of chronic traumatic encephalopathy comprising administration of an effective amount of aprepitant (otherwise known as emend, fosaprepitant, ivemend, L754030, ...  
WO/2015/000412A1
The present invention relates to a benzocyclobutene derivative and a preparation method and pharmaceutical application thereof. Specifically, the present invention relates to a compound expressed by formula (I) or a stereoisomer, hydrate...  
WO/2015/002150A1
[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound....  
WO/2015/002231A1
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)  
WO/2015/000370A1
The present invention provides pyrroloquinoline quinone lithium salt crystal and a preparation method and application thereof. Characteristic absorption peaks appear when the diffraction angles are 6.222±0.2, 7.379±0.2, 7.941±0.2, 23....  
WO/2015/001488A1
The present invention relates to extended-release tablets of paliperidone. It further relates to processes for the preparation of the extended-release tablets and methods of treating neurological disorders by administering the extended-r...  
WO/2015/000032A1
The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy.  
WO/2014/210596A1
Disclosed in certain embodiments is a method of treating an arrhythmia comprising administering to a patient in need thereof an effective amount of an opioid antagonist to treat the arrhythmia.  
WO/2014/209239A1
The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting ...  
WO/2014/210456A1
This disclosure relates to pyrazoline dihydroquinolone derivatives, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto...  
WO/2014/209033A1
Provided is a pharmaceutical composition for preventing or treating a cognitive impairment-related disease, the pharmaceutical composition including N-(2-hydroxyethyl)piperazine-N'(3-propane sulfonic acid), a pharmaceutically acceptable ...  
WO/2014/206427A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2014/207241A1
The present invention relates to a compound according to Formula (III) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof and its use.  
WO/2014/207122A1
Antagonists of TMEFF2 (Transmembrane protein with EGF-like and two follistatin-like domains 2) for use in the treatment or prevention of a neurodegenerative disease, in particular plaque related diseases like Alzheimer's disease are desc...  
WO/2014/206349A1
The present invention relates to an oxa-thia-bicyclo[3.2.1]octane derivative, a preparation method, and use of same, and particularly to an oxa-thia-bicyclo[3.2.1]octane derivative represented by the general formula (I) or a hydrate, a s...  
WO/2014/209094A1
The invention relates to pyridazin-3(2H)-one derivatives of general formulae (I) and (II), having an anti-inflammatory, analgesic, sedative, myorelaxant and anxiolytic activity. In formulae (I) and (II), X is O, S or N; Y is O or S; and ...  
WO/2014/206563A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2014/206899A1
The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.  

Matches 501 - 550 out of 106,020